Whether a person eats a cookie or devours the whole box could come down to the mood of microglia in their hypothalamus. Blocking activation of the region’s NLRP3 inflammasome could keep excessive ...

BUFFALO, NY-August 8, 2023 – A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 14, entitled, “Inhibiting ...

NodThera’s NLRP3 inhibitor has already proved its worth against Novo Nordisk’s blockbuster obesity drug in preclinical trials. Now, an early readout from a study in humans with obesity has again ...

Powered by Insilico’s proprietary Pharma.AI platform, the BBB (blood-brain barrier) penetrable molecule was designed as a potential treatment of various inflammation-related diseases, including gout ...

In a recent study published in Scientific Reports, researchers described the preclinical profile of JT002, a novel and orally bioavailable small molecule inhibitor of the NLR family pyrin ...

An experimental Ventyx Biosciences drug led to statistically significant reductions in blood levels of a protein that’s an indicator of cardiovascular risk, preliminary Phase 2 results that support ...

BioAge Labs, Inc. announced progress in their development pipeline, highlighting the advancement of their oral NLRP3 inhibitor BGE-102, with initial clinical data expected in the second half of 2025.